SRR934737
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.627
- INTERFERON_GAMMA_RESPONSE+0.615
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.536
- ALLOGRAFT_REJECTION+0.524
- IL6_JAK_STAT3_SIGNALING+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.477
- TGF_BETA_SIGNALING+0.450
- INFLAMMATORY_RESPONSE+0.439
- ANGIOGENESIS+0.418
Top 10 suppressed
- KRAS_SIGNALING_DN-0.360
- PANCREAS_BETA_CELLS-0.334
- MYOGENESIS-0.278
- OXIDATIVE_PHOSPHORYLATION-0.223
- HEDGEHOG_SIGNALING-0.146
- WNT_BETA_CATENIN_SIGNALING-0.062
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.050
- ADIPOGENESIS-0.025
- HEME_METABOLISM-0.016
- CHOLESTEROL_HOMEOSTASIS-0.006
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934753 | — | — | 0.953 |
| 2 | SRR934802 | — | — | 0.945 |
| 3 | SRR934934 | — | — | 0.943 |
| 4 | BS_J70GK8SM | Supratentorial Ependymoma | — | 0.937 |
| 5 | SRR934881 | — | — | 0.929 |
| 6 | SRR934864 | — | — | 0.924 |
| 7 | SRR934825 | — | — | 0.921 |
| 8 | SRR934925 | — | — | 0.916 |
| 9 | 738B9C39-A73F-4BD5-A8D4-3F75B9E14569 | — | — | 0.913 |
| 10 | SRR934962 | — | — | 0.913 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.627 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.615 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.536 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.524 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.520 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.477 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.450 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.439 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.418 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.406 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.396 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.376 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.376 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.363 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.345 | Inavolisib | — uncovered |
| COMPLEMENT | 0.344 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.334 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.334 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |